CHEMEROW DAVID I. 4

What Happened

David I. Chemerow, a director of AIM ImmunoTech (AIM), reported acquiring derivative securities on March 6, 2026. The filing shows purchase of 25 convertible preferred "shares" at $25,000 each (total $625,000) and acquisition of 50,000 derivative instruments reported at $0 cost (described in the filing as part of the same transaction). The Form 4 uses transaction code J (other acquisition) and lists these as derivative securities issued in connection with a rights offering — a purchase (acquisition) rather than a sale.

Key Details

• Transaction date: 2026-03-06; Form 4 filed: 2026-03-10.
• Reported amounts: 25 convertible preferred shares @ $25,000 each = $625,000; 50,000 derivative instruments @ $0.00.
• Transaction code: J (other acquisition/disposition).
• Shares owned after the transaction: not specified in the supplied excerpt of the filing.
• Footnotes from the filing:
  • F1: Each preferred share has a stated value of $1,000 and is convertible into 1,000 common shares; issued as part of a subscription right in a rights offering.
  • F3: Each warrant (or similar instrument) is exercisable for one common share at $1.00 and was issued as part of the rights offering.
  • F2: n/a (preferreds are perpetual).
• Timeliness: The Form 4 was filed four days after the transaction (filed three business days later). Form 4s are generally due within two business days of the transaction, so this filing appears to have been submitted late.

Context

• What these derivatives mean: the 25 convertible preferreds can be converted into common stock (per footnote, 1,000 common shares per preferred), and the 50,000 instruments appear to be warrants exercisable at $1.00 per common share. The warrants were reported at $0 because they were issued as part of the rights offering package.
• For retail investors: this is a purchase by an insider (often taken as a more informative signal than a sale), and the cash amount reported ($625k) is material. However, conversions/exercises and the eventual dilution from exercised warrants or converted preferreds can materially affect common share count.
• No indication in the provided data that any shares were immediately sold (no cashless exercise reported).